Enable JavaScript to visit this website.
Skip directly to content

Pfizer Canada Statement: EpiPen® Auto-Injector (0.3 mg) Supply Interruption


As a result of a supply interruption, Pfizer is experiencing a supply shortage of EpiPen auto-injectors in the 0.3 mg format in January 2018.  EpiPen is a medically necessary product with currently no alternatives on the market in Canada.  At this time, there is limited supply of auto-injectors at wholesalers, distributors and at pharmacies.  While we are working closely with our distributors to avoid long-term supply shortage at the store level, we expect a period of between two and four weeks of no inventory.  Additional limited inventory will be supplied at the beginning of February 2018 which will be placed under allocation and we will continue to manage supply carefully.

Pfizer has advised and is working with Health Canada on this situation and we are exploring remediation plans to address this situation.

We understand and regret the challenges this shortage poses to patients.  Ensuring continuity of the supply of our medicines is paramount, and this temporary supply interruption does not indicate an impact on the quality, safety or efficacy of EpiPen auto-injectors currently available on the Canadian market.  Pfizer fully realizes the importance of this medicine to our customers and patients, and has taken action to minimize the duration of the supply interruption, including efforts to expedite delivery of available supply.

For more information, please contact:

Questions of a Medical nature, please call: Pfizer Canada Medical Information @ 1-800-463-6001; www.pfizermedicalinformation.com

Questions from Trade customers, please call: Customer Relations @ 1-877-EPIPEN1 (1-877-374-7361).

If you are a member of the media, please call: Pfizer Canada Media Relations @ 1-866-9Pfizer (1-866-973-4937) email: [email protected]